Company news

CSPC Pharmaceutical Group Limited news

Latest news releases, newest first. Pick a year for every news release, call and deck from that year.

View company

Monthly return of equity issuer on movements in securities for the month ended 31 October 2026

November 2, 2026

Voluntary announcement - phase iii clinical trial of prusogliptin tablets in combination with dapagliflozin tablets and metformin hydrochloride extended-release tablets for the treatment of type 2 diabetes mellitus achieves positive topline results

November 2, 2026

Voluntary announcement - phase i/ii clinical trial of SYS6052 (recombinant herpes zoster virus vaccine (cho cells)) officially initiated in china

November 2, 2026

Voluntary announcement - phase i clinical trial of SYS6057 (recombinant respiratory syncytial virus vaccine (cho cells)) officially initiated in china

November 2, 2026

Voluntary announcement - phase i/ii clinical trial of SYS6043 for the treatment of advanced solid tumours officially initiated at the first centre in china

October 30, 2026

Unaudited financial information of cspc innovation pharmaceutical co., ltd. for the nine months ended 30 September 2026

October 28, 2026

Voluntary announcement - phase i clinical trial of SYS6077 injection for the treatment of advanced malignant tumours officially initiated at the first centre in china

October 28, 2026

Voluntary announcement - results from a phase i/ii clinical study of SYS6043 (B7-H3 adc) for the treatment of advanced breast cancer presented as a rapid oral presentation at the esmo congress 2026

October 27, 2026

Voluntary announcement - results from a phase i/ii clinical study of anti-PD-1/IL-15 bifunctional fusion protein SYS6090 (JMT108) monotherapy in advanced solid tumours presented as a rapid oral presentation at the esmo congress 2026

October 27, 2026

Voluntary announcement - results from a phase iii clinical study of anbenitamab in combination with docetaxel for injection (albumin-bound) (HB1801) for the first-line treatment of HER2-positive advanced breast cancer presented as a proffered paper presentation at the esmo congress 2026 and simultaneously published in the new england journal of medicine

October 26, 2026

Voluntary announcement - updated overall survival (os) results from a phase iii clinical study of anbenitamab for the treatment of HER2-positive advanced gastric cancer/gastro-oesophageal junction adenocarcinoma presented as a rapid oral presentation at the esmo congress 2026

October 26, 2026

Voluntary announcement - batoclimab injection (subcutaneous injection) obtains drug registration certificate from the nmpa

October 22, 2026

Voluntary announcement - phase iii clinical trial of SYS6043 for the first-line treatment of unresectable recurrent or metastatic triple-negative breast cancer officially initiated in china

October 22, 2026

Voluntary announcement - phase ii clinical trial of SYH2066 for the treatment of respiratory syncytial virus infection officially initiated in china

October 22, 2026

Voluntary announcement - phase i clinical trial of SYH2083 eye drops for the treatment of dry eye disease officially initiated in china

October 20, 2026

Voluntary announcement - grant of awarded shares pursuant to the 2026 share award scheme

October 16, 2026

Voluntary announcement - grant of awarded shares pursuant to the 2018 share award scheme

October 15, 2026

Voluntary announcement - SYS6088 injection (a tri-specific antibody) obtains clinical trial approval in China

October 15, 2026

Voluntary announcement - SYS6062 (antibody-drug conjugate) obtains clinical trial approval in China

October 15, 2026

Voluntary announcement - data from Phase I clinical study of SYS6002 as monotherapy for the treatment of advanced cervical cancer presented as a rapid oral presentation at the 2026 annual global meeting of the international gynecologic cancer society (igcs 2026)

October 8, 2026

Voluntary announcement - latest updates from 8 clinical trials to be presented at the ESMO congress 2026

October 5, 2026

Monthly return of equity issuer on movements in securities for the month ended 30 September 2026

October 2, 2026

Voluntary announcement - results of phase III clinical study of efmedaglutide alfa injection in combination with metformin in chinese adult patients with type 2 diabetes mellitus presented in a short oral discussion at the 62nd annual meeting of the european association for the study of diabetes (easd 2026)

September 30, 2026

Voluntary announcement - Phase Ib clinical trial of JMT206 injection for weight management in adult patients with overweight or obesity officially initiated at the first study centre in China

September 29, 2026

Voluntary announcement - recombinant herpes zoster vaccine (SYS6052) obtains clinical trial approval in the U.S.

September 29, 2026

Voluntary announcement - SYS6077 injection obtains clinical trial approval in China

September 28, 2026

Voluntary announcement - phase III clinical trial of becotatug (JMT101) in combination with osimertinib for the first-line treatment of locally advanced or metastatic NSCLC harbouring EGFR exon 20 insertion mutations achieves positive topline results

September 24, 2026

Voluntary announcement - phase III clinical trial of docetaxel for injection (albumin-bound) (HB1801) for the treatment of advanced breast cancer officially initiated in china

September 24, 2026

Notification letter to shareholder and change request form

September 17, 2026

Notification letter to non-registered holder and request form

September 17, 2026

Letter to new registered shareholders and reply form

September 17, 2026

2026 Interim report

September 17, 2026

Voluntary announcement - phase ii clinical trial of SYH2069 injection for the treatment of type 2 diabetes mellitus in adult patients officially initiated at the first centre in china

September 16, 2026

Voluntary announcement - SYS6010 granted breakthrough therapy designation by nmpa in china for the treatment of patients with actionable genomic alteration-negative non-squamous non-small cell lung cancer

September 15, 2026

Voluntary announcement - phase i/ii clinical trial data of SYS6010 in combination with enlonstobart for the treatment of systemic treatment-naive, actionable genomic alteration-negative advanced nsclc orally presented at the 2026 world conference on lung cancer (wclc)

September 14, 2026

Biparatopic HER2-targeting ADC JSKN003 Was Granted Another Breakthrough Therapy Designation for HER2-Positive Advanced Colorectal Cancer

October 20, 2025

Research Updates on a Phase III Clinical Trial of Anbenitamab (KN026) Presented at ESMO Congress 2025 LBA Oral Presentation Session

October 18, 2025

The New Drug Application for KN026 (Anbenitamab Injection) Has Been Accepted by the National Medical Products Administration

September 11, 2025

Madrigal Pharmaceuticals Enters into Exclusive Global License Agreement for Oral GLP-1 Receptor Agonist with CSPC Pharmaceutical Group Limited

July 30, 2025

CSPC Pharmaceutical Group: Voluntary announcement - "oseltamivir phosphate capsules" obtains drug registration approval

September 1, 2021

CSPC Pharmaceutical Group: Voluntary announcement - "alogliptin benzoate tablets" obtains drug registration approval

May 12, 2021

CSPC Pharmaceutical Group: Voluntary announcement - "sorafenib tosylate tablets" obtains drug registration approval

May 12, 2021

Voluntary announcement - passing of consistency evaluation for "doxorubicin hydrochloride liposome injection"

May 12, 2021

CSPC Pharmaceutical Group: Voluntary announcement - "sitagliptin phosphate tablets" obtains drug registration approval

May 12, 2021

Voluntary announcement - investigational first-in-class product SYSA1801 granted orphan-drug designation by the U.S. FDA

May 6, 2021

CSPC Pharmaceutical Group: Connected transaction - disposal of 49.5% equity interest in joint venture company /continuing connected transactions - master purchase agreement

April 30, 2021

Inside information - principal financial information of cspc innovation pharmaceutical co., ltd. for the three months ended 31 March 2021

April 26, 2021

CSPC Pharmaceutical Group: Voluntary announcement - nbl-012 obtains clinical trial approval in china

April 23, 2021

Voluntary announcement - application for marketing approval of "duvelisib capsules" accepted by nmpa

April 19, 2021

CSPC Pharmaceutical Group: Proposals for general mandates to buy-back shares and to issue shares and mandate to grant options, re-election of the retiring directors, and notice of annual general meeting

April 14, 2021

Older news releases →

Decks

The 5 newest of 17 decks. Every deck is listed under its year.